摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl(pent-4-en-1-yl)sulfide | 69632-05-9

中文名称
——
中文别名
——
英文名称
methyl(pent-4-en-1-yl)sulfide
英文别名
4-penten-1-yl methyl sulfide;pent-4-enyl methyl sulphide;4-pentenyl methyl sulfide;MeS(CH2)3CH=CH2;5-methylsulfanyl-pent-1-ene;Methyl--sulfid;5-(Methylsulfanyl)pent-1-ene;5-methylsulfanylpent-1-ene
methyl(pent-4-en-1-yl)sulfide化学式
CAS
69632-05-9
化学式
C6H12S
mdl
——
分子量
116.227
InChiKey
VLMMKBGQSJLXIH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    7
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    25.3
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS THAT INHIBIT MCL-1 PROTEIN<br/>[FR] COMPOSÉS INHIBANT LA PROTÉINE MCL-1
    申请人:AMGEN INC
    公开号:WO2017147410A1
    公开(公告)日:2017-08-31
    Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    本文提供了髓样细胞白血病1蛋白(Mcl-1)抑制剂,其制备方法,相关的药物组合物,以及使用这些物质的方法。例如,本文提供了化合物I的公式,及其药用盐和含有这些化合物的药物组合物。本文提供的化合物和组合物可以用于治疗癌症等疾病或症状。
  • Iridium-Catalyzed Hydrosilylation of Sulfur-Containing Olefins
    作者:Venu Srinivas、Yumiko Nakajima、Kazuhiko Sato、Shigeru Shimada
    DOI:10.1021/acs.orglett.7b02940
    日期:2018.1.5
    Hydrosilylation of various sulfur-containing olefins with (RO)3SiH has been achieved using iridium catalysts [IrX(cod)]2 (X = Cl, SPh). The catalysis is applicable to the chemoselective hydrosilylation of thioacetate, which enables the preparation of an industrially important silane coupling agent.
    使用铱催化剂[IrX(cod)] 2(X = Cl,SPh)已实现了各种含硫烯烃与(RO)3 SiH的氢化硅烷化。该催化可用于硫代乙酸酯的化学选择性氢化硅烷化,这使得能够制备工业上重要的硅烷偶联剂。
  • The directed Pauson-Khand reaction
    作者:Marie E. Krafft、Carmelinda A. Juliano、Ian L. Scott、Colin Wright、Michael D. McEachin
    DOI:10.1021/ja00005a038
    日期:1991.2
    The regioselectivity of the cobalt-mediated cocyclization of an alkene, an alkyne, and carbon monoxide has been shown to be directed by the use of a soft atom, either sulfur or nitrogen, tethered to the alkene partner by a carbon chain. Direction from the homoallylic position is more efficient thant from the allylic or bishomoallylic position. A rationale is proposed to explain this observation. Studies
    钴介导的烯烃、炔烃和一氧化碳共环化的区域选择性已被证明是通过使用一个软原子(硫或氮)来指导的,硫或氮通过碳链连接到烯烃伙伴上。来自同位烯丙基位置的方向比来自烯丙基或双烯丙基位置的方向更有效。提出了一个基本原理来解释这一观察结果。研究了不同烷基对硫和氮的影响以及其他修饰
  • Regiocontrol in the intermolecular cobalt-catalyzed olefin-acetylene cycloaddition
    作者:Marie E. Krafft
    DOI:10.1021/ja00211a048
    日期:1988.2.3
    Reactions de complexes de Co 2 (CO) 6 a coordinat acetylenique avec des sulfures ou amines homoallyliques: obtention de methylthio-2'- et dimethylamino-2' ethyl-5 cyclopentene-2ones
    反应 de Co 2 (CO) 6 a coordinat acetylenique avec dessulfes ou amines homoallyliques: obtention demethylthio-2'- et dimethylamino-2'ethyl-5 cyclopentene-2ones
  • Amino alcohol compound
    申请人:Nishi Takahide
    公开号:US20070191468A1
    公开(公告)日:2007-08-16
    A pharmaceutical composition is provided that has a low toxicity, demonstrates superior physicochemical properties and pharmacokinetics, and has superior peripheral blood lymphocyte count lowering activity. The pharmaceutical composition contains a compound having general formula (I): [Chemical Formula 1] (wherein R 1 represents a methyl group or an ethyl group, R 2 represents a methyl group or an ethyl group, and R 3 represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.
    提供了一种低毒性、表现出优越的物理化学性质和药代动力学,并具有优越的外周血淋巴细胞计数降低活性的药物组合物。该药物组合物包含具有一般式(I)的化合物:[化学式1](其中R1代表甲基基团或乙基基团,R2代表甲基基团或乙基基团,R3代表苯基,该苯基被1至3个取自卤原子、较低烷基基团、环烷基团、较低烷氧基团、卤代较低烷基基团、较低脂肪酰基基团和氰基的取代基所取代),以及其药理学上可接受的盐或药理学上可接受的酯。
查看更多